Regen Biopharma files Q2 2021 10-Q, ends reporting delinquency; plans convertible debt settlement to curb dilution

Regen BioPharma Inc

Filed quarterly report for period ended June 30, 2021; now current on SEC filings.
No convertible debt issued since July 2020; no plans to issue additional convertible instruments.
Intends to negotiate settlement of remaining convertible notes to eliminate or limit dilution; no assurances of favorable terms or execution.
Remaining noteholders may not agree to terms, and any settlement may not be on terms favorable to the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.